Publications
74 results found
Vidal L, Blagden S, Attard G, et al., 2005, Making sense of antisense, EUROPEAN JOURNAL OF CANCER, Vol: 41, Pages: 2812-2818, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 39
Steele N, Vidal L, Plumb J, et al., 2005, A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 200S-200S, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 12
Pacey S, Plummer RE, Attard G, et al., 2005, Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies., 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 205S-205S, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 15
Blagden S, Thomas A, De-Bono JS, et al., 2005, Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors, 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 226S-226S, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Attard G, Kitzen JJ, de Bono J, et al., 2005, A phase 1b study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors, 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Publisher: AMER SOC CLINICAL ONCOLOGY, Pages: 232S-232S, ISSN: 0732-183X
Blagden S, de Bono J, 2005, Drugging cell cycle kinases in cancer therapy, CURRENT DRUG TARGETS, Vol: 6, Pages: 325-335, ISSN: 1389-4501
- Author Web Link
- Cite
- Citations: 79
Blagden SP, Kaye SB, 2005, Docetaxel in the management of ovarian cancer, EXPERT REVIEW OF ANTICANCER THERAPY, Vol: 5, Pages: 203-214, ISSN: 1473-7140
- Author Web Link
- Cite
- Citations: 8
Blagden SP, Charman SC, Sharples LD, et al., 2003, Performance status score: do patients and their oncologists agree?, BRITISH JOURNAL OF CANCER, Vol: 89, Pages: 1022-1027, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 142
Blagden SP, Glover DM, 2003, Polar expeditions - provisioning the centrosome for mitosis, NATURE CELL BIOLOGY, Vol: 5, Pages: 505-511, ISSN: 1465-7392
- Author Web Link
- Cite
- Citations: 112
Blagden SP, Foskett MA, Fisher RA, et al., 2002, The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours, BRITISH JOURNAL OF CANCER, Vol: 86, Pages: 26-30, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 30
Corrie P, Mayer A, Shaw J, et al., 2002, Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients, Br J Cancer, Vol: 87, Pages: 716-719
A phase II study was undertaken to determine the safety of combining flutamide with gemcitabine, with response rate being the primary end point. Twenty-seven patients with histologically proven, previously untreated, unresectable pancreatic adenocarcinoma received gemcitabine, 1 g m(-2) intravenously on days 1, 8 and 15 of a 28 day cycle, and flutamide 250 mg given orally three times daily. Treatment was halted if there was unacceptable toxicity, or evidence of disease progression. Toxicity was documented every cycle. Tumour assessment was undertaken after cycles 2 and 4, and thereafter at least every additional four cycles. One hundred and seventeen cycles of treatment were administered, median four cycles per patient (range 1-18). Gemcitabine combined with flutamide was well tolerated, with most toxicities being recorded as grade 1 or 2 and only nine treatment cycles associated with grade 3 toxicity. The most frequent toxicity was myelosuppression. One case of transient jaundice was recorded. The commonest symptomatic toxicity was nausea and vomiting. The response rate was 15% (four partial responses), median survival 6 months and 22% of patients were alive at 1 year. These results suggest antitumour activity of the combination therapy to be equivalent to single agent gemcitabine. doi:10.1038/sj.bjc.6600523 www.bjcancer.comCopyright 2002 Cancer Research UK
Seckl MJ, Blagden SP, Foskett MA, et al., 1999, Outcome in patients who become pregnant within 12 months after completing single and multiple agent chemotherapy for gestational trophoblastic disease (GTD), EUROPEAN JOURNAL OF CANCER, Vol: 35, Pages: S231-S231, ISSN: 0959-8049
Blagden SP, Earl HM, Brenton J, et al., 1999, A study of epirubicin, cisplatin and prolonged infusional 5-FU (ECF) treatment for relapsed epithelial ovarian cancer, BRITISH JOURNAL OF CANCER, Vol: 80, Pages: 107-107, ISSN: 0007-0920
Lo SK, Montgomery JN, Blagden S, et al., 1999, Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics, LANCET, Vol: 353, Pages: 2038-2039, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 5
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.